Home › Compare › RAHGF vs ABBV
RAHGF yields 2000000.00% · ABBV yields 3.06%● Live data
📍 RAHGF pulled ahead of the other in Year 1
Combined, RAHGF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of RAHGF + ABBV for your $10,000?
Roan Holdings Group Co., Ltd., through its subsidiaries, provides financial, insurance, and healthcare related solutions to individuals, and micro, small, and medium-sized enterprises in China. It offers health management, health big data management, and blockchain technology-based health information management, as well as asset management, factoring, and consumer financing services to the employees of large institutions. Further, it provides supply chain management, financial advisory, consulting services related to debt collection, and management and assessment services, as well as loans to third parties, SME and consumer financing, equity, currency integrated payment application, travel consumption, multimedia real-time multi-threaded interactive technology application, oncology treatment and products, and one-stop internet service platform. The company was formerly known as China Lending Corporation and changed its name to Roan Holdings Group Co., Ltd. in January 2020. Roan Holdings Group Co., Ltd. was founded in 2009 and is based in Hangzhou, the People's Republic of China.
Full RAHGF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.